An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

Leukemia and Lymphoma

Volumn 55, Issue 11, 2014, Pages 2466-2476

  Nam, Soo Jeong ^a,b   Go, Heounjeong ^a,b,c   Paik, Jin Ho ^d   Kim, Tae Min ^a   Heo, Dae Seog ^a   Kim, Chul Woo ^a,b   Jeon, Yoon Kyung ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

Diffuse large B cell lymphoma; M2 macrophages; Regulatory T cells; Tumor microenvironment; Tumor associated macrophages

Indexed keywords

ANTIGEN; CD163 ANTIGEN; CD204 ANTIGEN; CD68 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; MSR1 PROTEIN, HUMAN; SCAVENGER RECEPTOR A;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; DISEASE FREE SURVIVAL; DRUG EFFECTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; RECEPTORS, CELL SURFACE; SCAVENGER RECEPTORS, CLASS A; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VINCRISTINE;

EID: 84912123889     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.879713     Document Type: Article

References (34)

1. Swerdlow S, Campo E, Harris NL, et al. WHO classif cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
2. Jafe ES, Harris NL, Vardiman JW, et al. Hematopathology. Philadelphia, PA: Elsevier Health Sciences; 2011.
3. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
4. Monti S, Savage KJ, Kutok JL, et al. Molecular prof ling of dif use large B-cell lymphoma identif es robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861.
5. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78.
6. Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-446.
7. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-2174.
8. Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010;16:637-650.
9. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-885.
10. Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301-308.
11. Zhang W, Wang L, Zhou D, et al. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specif ed. Leuk Lymphoma 2011; 52: 46-52.
12. Komohara Y, Niino D, Saito Y, et al. Clinical signif cance of CD163 tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci 2013; 104: 945-951.
13. Niino D, Komohara Y, Murayama T, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 2010; 60: 278-283.
14. Lin ZX, Bai B, Cai QC, et al. High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T-and natural killer cell lymphomas. Med Oncol 2012; 29: 3522-3528.
15. Hasselblom S, Hansson U, Sigurdardottir M, et al. Expression of CD68 + tumor-associated macrophages in patients with dif use large B-cell lymphoma and its relation to prognosis. Pathol Int 2008; 58: 529-532.
16. Wada N, Zaki MA, Hori Y, et al. Tumour-associated macrophages in dif use large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012; 60: 313-319.
17. Cai QC, Liao H, Lin SX, et al. High expression of tumor-inf ltrating macrophages correlates with poor prognosis in patients with dif use large B-cell lymphoma. Med Oncol 2012; 29: 2317-2322.
18. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
19. Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related infammation. J Leukoc Biol 2009;86:1065-1073.
20. Schmieder A, Michel J, Schonhaar K, et al. Dif erentiation and gene expression profile of tumor-associated macrophages. Semin Cancer Biol 2012;22:289-297.
21. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3 + regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490-500.
22. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-811.
23. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3 + regulatory T cells with improved survival in germinal center-like dif use large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93:193-200.
24. Kim WY, Jeon YK, Kim TM, et al. Increased quantity of tumor-inf ltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009; 20: 1688-1696.
25. Hasselblom S, Sigurdadottir M, Hansson U, et al. The number of tumour-infltrating TIA-1 + cytotoxic T cells but not FOXP3 + regulatory T cells predicts outcome in dif use large B-cell lymphoma. Br J Haematol 2007;137:364-373.
26. Paik JH, Go H, Nam SJ, et al. Clinicopathologic implication of A20/TNFAIP3 deletion in dif use large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment. Leuk Lymphoma 2013; 54: 1934-1941.
27. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classif es dif use large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502.
28. Komohara Y, Hirahara J, Horikawa T, et al. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006;54:763-771.
29. Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004;36:347-354.
30. Kong LQ, Zhu XD, Xu HX, et al. The clinical signif cance of the CD163 + and CD68 + macrophages in patients with hepatocellular carcinoma. PLoS One 2013; 8: e59771.
31. Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-inf ltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96:269-276.
32. Lee NR, Song EK, Jang KY, et al. Prognostic impact of tumor inf ltrating FOXP3 positive regulatory T cells in dif use large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247-256.
33. Taskinen M Karjalainen-Lindsberg ML, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784-5789.
34. Leidi M, Gotti E, Bologna L, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more ef ciently than m1 cells in vitro. J Immunol 2009;182:4415-4422.